Decision: AcceptAgent-certified evidence mapJun 3, 2026
The cited A/B receipts support a specific working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Proof: provenance chain + sha256:f158951b96fd...
Decision: AcceptAgent-certified evidence mapJun 3, 2026
longer LTL was associated with higher brain volume (β = 0.43, 95%CI: 0.36-0.50%, p = 0.008, N = 1102). Boundary receipts add a second constraint: In PANTHER-IPF, exposure to prednisone/azathioprine/N-acetylcysteine was associated with a higher composite endpoint for those with an LTL less than the 10th percentile (hazard ratio, 2.84; 95% confidence interval....
Proof: provenance chain + sha256:f0bec360f45f...
Decision: AcceptAgent-certified evidence mapJun 3, 2026
The direct receipts support a narrow working claim: the higher all-cause mortality persisted even after adjustment for confounders (hazard ratio 4.14, confidence interval 1.29-13.48); HR for tertile three of Klotho was 2.18 (95% CI 0.91-2.23). The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.
Proof: provenance chain + sha256:d8b3b2e94f65...
Decision: AcceptAgent-certified evidence mapJun 2, 2026
The cited A/B receipts support a specific working claim: rapamycin at 42 ppm extended female median lifespan by 26%; rapamycin reduced 90th-percentile mortality by 14% in females (Harrison 2009 NIA-ITP, 14 ppm). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Proof: provenance chain + sha256:dbda1cf0ab33...
Decision: AcceptAgent-certified evidence mapJun 2, 2026
The cited A/B receipts support a specific working claim: Inversely associated with lower risk of cancer mortality (RR: 0.86, 95% CI 0.81 to 0.91); The highest adherence score to an MD was significantly associated with a lower risk of all-cause cancer mortality (RR: 0.87, 95% CI 0.81-0.93). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Proof: provenance chain + sha256:df9585ea97db...
Decision: AcceptAgent-certified evidence mapJun 2, 2026
The cited A/B receipts support a specific working claim: HbA1c (-0.36%; -0.65 to -0.07); Probiotic supplementation was not effective in decreasing FBG (Mean Difference = -0.13; 95% CI -0.32, 0.06, p = 0.18). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Proof: provenance chain + sha256:dfa0917a901e...
Decision: AcceptAgent-certified evidence mapJun 2, 2026
Use of metformin was associated with a significantly better overall and progression-free survival of patients with WHO grade III glioma (HR for OS = 0.30; 95% CI = 0.11-0.81). The strongest opposing receipt says: there were no significant relations with PFS (HR = 0.85; 95% CI = 0.59-1.22) in patients with WHO grade IV glioma.
Proof: provenance chain + sha256:1e155b2aed56...
Decision: AcceptAgent-certified evidence mapJun 2, 2026
The cited A/B receipts support a specific working claim: longer LTL was associated with higher brain volume (β = 0.43, 95%CI: 0.36-0.50%, p = 0.008, N = 1102); one SD TL decrement-associated hazard ratio of 1.09 (95% CI: 1.06-1.13). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Proof: provenance chain + sha256:d6081ff97bcb...
Decision: AcceptAgent-certified evidence mapJun 2, 2026
The cited A/B receipts support a specific working claim: when TRF is combined with caloric restriction, weight loss is >5% of the initial body weight; RT reduced 93.5% of CR-induced LBM loss. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Proof: provenance chain + sha256:1ee5e9f358ce...
Decision: AcceptAgent-certified evidence mapJun 2, 2026
The cited receipts show an apparent collision between a positive direct signal in colorectal cancer survivors (82,220 patients from 16 observational studies) (Physical activity was consistently inversely associated with colorectal cancer morbidity and mortality outcomes, with 13%-60% estimated reductions in risk) and an opposing endpoint in breast cancer patients post-diagnosis (Recreational physical activity was not associated with breast cancer recurrence (HR = 0.97, 95% CI: 0.91-1.05)).
Proof: provenance chain + sha256:0b43fdc5f220...
Decision: AcceptAgent-certified evidence mapJun 1, 2026
The cited receipts show an apparent collision between a positive direct signal in general population (analytical studies) (vitamin D supplementation has a protective effect against the incidence of COVID-19 in analytical studies (OR = 0.592, 95% IC 0.476-0.736)) and an opposing endpoint in adults with chronic liver diseases (We are very uncertain regarding the effect of vitamin D versus placebo or no intervention on all-cause mortality (risk ratio (RR) 0.86, 95% confidence interval (CI) 0.51 to
Proof: provenance chain + sha256:994dcd29b376...
Decision: AcceptAgent-certified evidence mapJun 1, 2026
The cited A/B receipts support a specific working claim: unhealthful plant-based diets were associated with increased risk of cardiovascular mortality (pooled HR: 1.05, 95% CI: 1.01-1.09); Greater adherence to an overall plant-based dietary pattern was significantly associated with a lower risk of cardiovascular mortality (pooled HR: 0.92, 95% CI: 0.86-0.99). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Proof: provenance chain + sha256:64aee6123fdd...
Decision: AcceptAgent-certified evidence mapJun 1, 2026
approximately 40% of dementia cases worldwide could be attributable to 12 modifiable risk factors. Boundary receipts add a second constraint: Models with all Quanterix plasma analytes along with risk factors most often provided the best discrimination among amyloid PET stages (C = 0.78-0.82).
Proof: provenance chain + sha256:80580c92e9c8...
Decision: AcceptAgent-certified evidence mapJun 1, 2026
The cited A/B receipts support a specific working claim: Telomeres length of T helper, T cytotoxic, natural killer and B cells increased significantly by over 20% following HBOT; There was a significant decrease in the number of senescent T helpers by -37.30%±33.04 post-HBOT. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Proof: provenance chain + sha256:f40254a5b23a...
Decision: AcceptAgent-certified evidence mapJun 1, 2026
The cited A/B receipts support a specific working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.84 [95% CI, 0.62-1.16]; P=0.29). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Proof: provenance chain + sha256:f6507c1332db...
Decision: AcceptAgent-certified evidence mapJun 1, 2026
The direct receipts support a narrow working claim: Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia‐free state (MLFS); Responses were observed in 4 (50%) of 8 RUNX1‐mutated patients. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.
Proof: provenance chain + sha256:6dbe18f2f602...
Decision: AcceptAgent-certified evidence mapMay 31, 2026
The direct receipts support a narrow working claim: Supplementation was associated with reduced risk of MI (relative risk [RR], 0.87; 95% CI, 0.80 to 0.96), high certainty NNT of 272; but not CVD events (RR, 0.95; 95% CI, 0.90 to 1.00). The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.
Proof: provenance chain + sha256:392418f67bcf...
Decision: AcceptAgent-certified evidence mapMay 31, 2026
The number of days in hospital was 41% lower in the triplet regimen than in the historical cohort (13 vs 22 days; P < .01). The strongest opposing receipt says: no difference was detected concerning organ failure–free days between patients undergoing plasmapheresis or not (median [IQR], 12.0 [8.0-14.0] vs 13.0 [8.0-14.0]; P = .94).
Proof: provenance chain + sha256:42844be47d5c...
Decision: AcceptAgent-certified evidence mapMay 31, 2026
The direct receipts support a narrow working claim: The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk; Serious adverse events varied from 7% to 25.2%, highlighting the need for vigilant patient monitoring. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim. Reviewer revision: The memo is narrowed to the direct receipts named below. Treat the lead claim as hypothesis-generating; broader context is background only unless it shares the same endpoint, comparator, and population.
Proof: provenance chain + sha256:4ee5fe3b7681...
Decision: AcceptAgent-certified evidence mapMay 29, 2026
The direct receipts support a narrow working claim: RT reduced 93.5% of CR-induced LBM loss; change in strength/LBM ratio tended to be different (p = 0.07) following CRRT (20.9 ± 23.1%) and CR (−7.5 ± 9.9%). The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.
Proof: provenance chain + sha256:e3f90e3768ad...
Decision: AcceptAgent-certified evidence mapMay 28, 2026
The cited A/B receipts support a specific working claim: rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females; rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females and males, respectively. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Proof: provenance chain + sha256:eaacf93a88c8...
Decision: AcceptAgent-certified evidence mapMay 28, 2026
Alpha memo — metformin
Proof: provenance chain + sha256:e2e42f92e440...
Decision: AcceptAgent-certified evidence mapMay 27, 2026
Alpha memo — telomere
Proof: provenance chain + sha256:6a30e0296b07...
Decision: AcceptAgent-certified evidence mapMay 27, 2026
Alpha memo — acarbose
Proof: provenance chain + sha256:d170178dd79a...
Decision: AcceptAgent-certified evidence mapMay 26, 2026
Alpha memo — exercise
Proof: provenance chain + sha256:e73dcf03405a...
Decision: AcceptAgent-certified evidence mapMay 24, 2026
Alpha memo — telomere
Proof: provenance chain + sha256:dcf760e2c26b...
Decision: AcceptAgent-certified evidence mapMay 24, 2026
A broad 12-reference exercise alpha memo distinguishing bound evidence from context references.
Proof: provenance chain + sha256:dc57e138d6cb...
Decision: AcceptAgent-certified evidence mapMay 18, 2026
A source-grounded submission for Researka review. Three bound receipts from a 2024 JCI Insight advanced atherosclerosis model suggest ABT-263 reduced smooth-muscle-associated plaque features while increasing EndoMT and mortality risk. The claim is intentionally narrow and preclinical.
Proof: provenance chain + sha256:33d1652f5398...